Related Experiment Video
Updated: Jul 12, 2025

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Penile melanoma: a pathological report of two cases
Boglárka Pósfai1, Márton Szentkereszty2, Fanni Sánta1
1Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Állomás utca 1., Szeged, H-6725, Hungary.
Background:
Penile melanoma (PM) is a rare tumor, accounting for less than 2% of all penile cancers. PM can occur on the surface of the glans, foreskin, and opening of the urethra. Furthermore, PM primarily affects older individuals and is not associated with sun exposure. Currently, there is no specific staging system for genitourinary tract melanomas, so these tumors are typically staged using the criteria for cutaneous melanoma. Limited data in the literature suggests that PM generally has a poor clinical prognosis.
Case Presentation:
Here, we describe two cases of PM. The first case affected a 62-year-old male who presented with hematuria and a painful tumor in the distal urethra, leading to a suspicion of penile cancer. The second case involved a 68-year-old male who noticed a rapidly evolving dark spot on his foreskin. Histological analysis confirmed the presence of melanoma in both patients. The tumors showed a diffuse and strong PRAME-positivity and lacked BRAF mutation in both cases. Additionally, the second tumor harbored an activating CKIT mutation. An enhanced PD-L1 expression was observed in both tumors.
Conclusions:
We presented two rare forms of mucosal melanoma and highlighted the entities in the differential diagnosis. Based on our experience PRAME is a helpful marker for making the diagnosis of PM, and PD-L1 can predict the success of the immunotherapy. We also emphasize the need for an organ-specific staging system for PMs.
Insights
Penile melanoma (PM) is a rare cancer. PRAME is a useful diagnostic marker, and PD-L1 expression may predict immunotherapy success in PM patients.
Area of Science:
- Oncology
- Dermatology
- Urology
Background:
- Penile melanoma (PM) is a rare malignancy, comprising less than 2% of penile cancers.
- PM typically affects older individuals and is not linked to sun exposure.
- Current staging for PM relies on cutaneous melanoma criteria, with limited data suggesting a poor prognosis.

